Selection of patients with advanced prostate cancer who are eligible for salvage radiation therapy could be improved with the use of radiocholine PET/CT, according to a review of recent research published today in the Journal of Nuclear Medicine . {read more here}

The amyloid PET agent F-18 flutemetamol (Vizamyl) was the topic of two scientific sessions at the Alzheimer’s Association International Conference (AAIC), which concluded yesterday in Copenhagen. Results of one study showed how patients with mild cognitive impairment (MCI) whose scans were positive for flutemetamol were 2.5 times more likely to progress to Alzheimer’s disease. Another study of early onset dementia patients showed improvements in clinical decision making and clinician confidence as a result of information gleaned from flutemetamol PET. {read more here}

Tau PET imaging has only recently been catching up to amyloid imaging in neurodegenerative disease and dementia research, but tau may be more of the culprit in cognitive decline than other naturally occurring proteins like amyloid. Finding tau deposition in the brain could be a way to verify Alzheimer’s prior to the arrival of all the characteristic symptoms, according to a study presented during this week’s Alzheimer’s Association International Conference (AAIC) 2014. {read more here}

Eight cardiologists in St. Louis decided to return to private practice after being asked by the Mercy Clinic to break their contract early and sign a new nationwide contract, the St. Louis Business Journal reported. Their current contract expires May 31, 2015. {read more here}